MedJ Takes You to WCLC 2025
Geoffrey Liu, MD, Princess Margaret Cancer Centre in Canada presented updated data from the TRUST-II study, revealing the breakthrough efficacy and favorable safety profile of taletrectinib in treating ROS1-positive NSCLC. He highlighted its exceptional potential to overcome drug-resistant mutations and strong CNS penetration, marking a new milestone in ROS1-targeted therapy.